Hints and tips:
Showing results for Takeda Pahrmaceuticals America, Inc.
Related Special Reports
...It hasn’t been an easy feat in America’s profoundly unequal credit system, Bloomberg writes....
...Drop us a line and join the conversation: Due.Diligence@FT.com America’s largest shopping mall owner is buying up its tenants Mall operator Simon Property Group has a problem....
...Another potential pitfall for Beam, under Japanese ownership, is the impact of North America’s cannabis craze....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...newsletter if you liked it.— The Due Diligence team Follow the FT’s deals team Arash Massoudi in London — @ArashMassoudi Javier Espinoza in London — @JavierespFT James Fontanella-Khan in New York — @JFK_America...
...Japanese pharma group Takeda weighs bid for Shire In the latest sign of the revived appetite for dealmaking among drugmakers, Japan’s Takeda Pharmaceutical indicated its interest in buying Shire, the UK-listed...
...The two Wall Street investment banks were followed by JPMorgan, Citigroup and Bank of America, according to Thomson Reuters data....
...The European gas market was “stable”, Taiyo said, noting it was second in size only to North America....
...Mega deals like Sprint/T-Mobile, Takeda/Shire, and Comcast’s pending conquests have made M&A a crucial driver of the loan market....
...Falls for some banks were much worse: Deutsche Bank’s investment banking revenues were down 27 per cent, Bank of America’s were down 13 per cent, Citi and JPMorgan were both down 10 per cent....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...(NYT) Down on Shire Japan’s Takeda continues to face stiff resistance from its own investors as it tries to pull off a risky deal for struggling pharma group Shire....
...Separately, Hikma disclosed on Thursday that it will expand its licensing and distribution pact with Japan’s Takeda Pharmaceuticals that will add new products to its Middle East and North Africa portfolio...
...Thomas Sheehan, head of global healthcare at Bank of America Merrill Lynch, said despite the slowdown the fundamentals for dealmaking remained unchanged and activity was bound to pick up again....
...Cancer drug maker Takeda Pharmaceutical, fell 2.6 per cent following Trump’s comments....
...This month it completed enrolment of 20,100 children in Latin America and Asia for a large-scale clinical trial of its new vaccine against dengue, an important public health problem in the tropics....
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...A portfolio of respiratory drugs bought from Takeda of Japan will provide an immediate lift to sales while US biotech companies ZS and Acerta were both acquired with an eye on the longer term....
...Alongside this organic progress, we also continued to invest in our main therapy areas through key agreements with Acerta Pharma, ZS Pharma, and Takeda....
...The investment came a day after AstraZeneca agreed to pay Takeda of Japan $575m for a portfolio of respiratory medicines and a month after it bought ZS Pharma, a US biotech company, for $2.7bn....
...Cash-rich Japanese drugmakers have been on a spending spree ahead of the so-called “patent cliff”, highlighted by Takeda Pharmaceutical’s $13.7bn purchase of Nycomed, the Swiss drugmaker, in 2011....
...“The Japanese market could certainly deserve some further consolidation,” says François-Xavier Roger, chief financial officer of Takeda, Japan’s biggest drugmaker....
...The $9bn punitive damages the US jury imposed on Takeda and Eli Lilly show the anger the industry will face if it doesn’t clean itself up. michael.skapinker@ft.com Twitter: @Skapinker...
...Nycomed, now part of Takeda of Japan, owns the rights to the medicine and licensed it exclusively in the US to Wyeth, which is now part of Pfizer....
...Takeda of Japan last year acquired Nycomed, bringing it a substantial portfolio of medicines in emerging markets led by Russia. Additional reporting by Andrew Jack in London...
International Edition